Schizophrenia Research
Volume 92, Issue 1 , Pages 95-102 , May 2007

A clinical study of the association of antipsychotics with hyperlipidemia

  • Jose de Leon

      Affiliations

    • University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, United States
    • University of Kentucky Mental Health Research Center at Western State Hospital, Hopkinsville, KY, United States
    • Department of Psychiatry and Institute of Neurosciences, University of Granada, Granada, Spain
    • Corresponding Author InformationCorresponding author. Mental Health Research Center at Eastern State Hospital, 627 West Fourth St., Lexington, KY 40508, United States. Tel.: +1 859 246 7487; fax: +1 859 246 7019.
    • ,
  • Margaret T. Susce

      Affiliations

    • University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, United States
    • University of Kentucky Mental Health Research Center at Western State Hospital, Hopkinsville, KY, United States
    • ,
  • Maria Johnson

      Affiliations

    • University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, United States
    • University of Kentucky Mental Health Research Center at Western State Hospital, Hopkinsville, KY, United States
    • ,
  • Mike Hardin

      Affiliations

    • University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, United States
    • University of Kentucky Mental Health Research Center at Western State Hospital, Hopkinsville, KY, United States
    • ,
  • Lana Pointer

      Affiliations

    • University of Kentucky Mental Health Research Center at Eastern State Hospital, Lexington, KY, United States
    • University of Kentucky Mental Health Research Center at Western State Hospital, Hopkinsville, KY, United States
    • ,
  • Gualberto Ruaño

      Affiliations

    • Genomas, Inc., Hartford, CT 06106, United States
    • ,
  • Andreas Windemuth

      Affiliations

    • Genomas, Inc., Hartford, CT 06106, United States
    • ,
  • Francisco J. Diaz

      Affiliations

    • Department of Statistics, Universidad Nacional, Medellín, Colombia

Received 8 August 2006 ,Revised 30 December 2006 ,Accepted 4 January 2007.

References 

  1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry. 1999;156:1686–1696
  2. Baptista T, Kin NMKNY. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry. 2002;35:205–219
  3. Baldessarini RJ. Chemotherapy in Psychiatry. Cambridge, MA: Harvard University Press; 1985;
  4. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol. Med. 1999;29:697–701
  5. Cohen J. A power primer. Psychol. Bull. 1992;112:155–159
  6. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J. Clin. Psychiatry. 2006;67:789–797
  7. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice (review). Biol. Psychiatry. 2005;59:990–996
  8. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353:1209–1223
  9. Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report (letter). J. Clin. Psychiatry. 2006;67:1473–1474
  10. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. Physical health monitoring of patients with schizophrenia. Am. J. Psychiatry. 2004;161:334–1349
  11. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J. Clin. Psychopharmacol. 2001;21:369–373
  12. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004;70:1–17
  13. Muñoz A, Xu J. Models for the incubation of AIDS and variations according to age and period. Stat. Med. 1996;15:2459–2473
  14. Panz VR, Raal FJ, Paiker J, Immelman R, Miles H. Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids. Cardiovasc. J. South. Afr. 2005;16:112–117
  15. Ritchie JD, Miller CK, Smiciklas-Wright H. Tanita foot-to-foot bioelectrical impedance analysis system validated in older adults. J. Am. Diet Assoc. 2005;105:1617–1619
  16. Ruaño, G., Goethe, J.W., Caley, C., Woolley, S., Holford, T.R., Kocherla, M., Windemuth, A., Leon, J.D., in press. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry [Electronic publication ahead of print 2 Jan 2007].
  17. Susce MT, Villanueva N, Diaz FJ, de Leon J. Obesity and associated complications in patients with severe mental illnesses: a cross-sectional survey. J. Clin. Psychiatry. 2005;66:167–173
  18. Woodward M. Epidemiology: Study Design and Data Analysis. Boca Raton: Chapman & Hall/CRC; 1999;
  19. Woods SW. Chlorpromazine equivalent dose for the newer atypical antipsychotics. J. Clin. Psychiatry. 2003;64:663–667

PII: S0920-9964(07)00067-9

doi: 10.1016/j.schres.2007.01.015

Schizophrenia Research
Volume 92, Issue 1 , Pages 95-102 , May 2007

Article Tools